Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis James PhillipsJuly 22, 2022
Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis James PhillipsJuly 14, 2022
Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis James PhillipsJune 13, 2022
Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis James PhillipsMay 23, 2022
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress James PhillipsMay 16, 2022
Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update James PhillipsApril 6, 2022
Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection James PhillipsMarch 30, 2022
Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection James PhillipsMarch 24, 2022
Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC James PhillipsMarch 22, 2022
Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx‑99 for the Prevention of H3N2 Influenza Infection James PhillipsMarch 15, 2022
Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference James PhillipsMarch 8, 2022
Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference James PhillipsFebruary 7, 2022
Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection James PhillipsJanuary 20, 2022
Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis James PhillipsJanuary 18, 2022
Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company James PhillipsJanuary 11, 2022
Petra Acquisition, Inc. Announces Share Redemption Backstop and Forward Purchase Agreements in Connection with Revelation Biosciences, Inc. Business Combination James PhillipsDecember 22, 2021
Petra Acquisition, Inc. Announces Special Meeting of Stockholders to Approve Business Combination with Revelation Biosciences, Inc. James PhillipsDecember 16, 2021
Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza James PhillipsDecember 1, 2021
Revelation Biosciences Inc. Announces Creation and Appointments to Scientific Advisory Board James PhillipsNovember 29, 2021
